Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Amarin Shares Up Sharply on Increased Revenues and Vascepa's Progress

Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa. Amarin Corp. (AMRN:NASDAQ) ADR shares are up sharply today after the com...

Fed Cuts Rates, Causing Gold to See-Saw

Yesterday, that was already the third time this year when the Fed cut interest rates. In response, the price of gold erased earlier losses. That sounds a bit fishy. What is going on? Fed Lowers Interest Rates by 25 Basis Points Yesterday, the FOMC published the monet...

Fed Cuts and Gold Drops. Again

History may not repeat itself to the letter but it certainly rhymes. That’s what the Fed watchers would say now. The Fed cut the interest rates for the second time this year and the price of gold declined again. What is going on? Fed Trims Interest Rates by ...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANG...

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. Clinical-stage biotechnology...

Is the Trade War a Catalyst for Gold?

Although most of the precious metals sector has trended lower in recent months, Gold has held up well. It and the other, weaker components of precious metals got a boost on Monday when China retaliated with tariffs of its own. There has been little follow through since. ...

Rally or New Bull Market?

In recent days the market has moved from expecting a rate cut by January 2020 to now expecting as much as three rate cuts by then. As a result both Gold and gold stocks launched higher, forming a “three white soldiers” bullish reversal pattern. Last w...

Crude Oil Going Nowhere Despite the Rising Tensions and Supply Cuts?

Crude oil bulls proved weaker and the strength they attempted to project yesterday, evaporated to a considerable degree. Neither today, they appear any stronger. Given the rising geopolitical tensions in the Middle East, one could expect a stronger performance. Additionally, O...

Benefactor of Interest Rate Cuts

Last week for the first time since 2008, the Federal Reserve cut interest rates. But was this rate cut needed? The Fed has been trying to force feed consumers who contribute about 70% to GDP to keep borrowing and spending. The plan has been working thus far as the economic e...
1 2 3 4 5 6 7 8 9 10 ...